19 Nov 2021

2021 AGM - Chairman Address

(1) Key Markets are Victoria, New South Wales, Queensland, South Australia and Northern Territory combined 1 ASX Announcement Monash IVF Group Limited (ASX: MVF) 19 November 202 1 Chairman Address by Mr. Richard Davis Monash IVF Group Limited Annual General Meeting Prior to handing over to Mr Michael Knaap, CEO, I would like to provide some commentary on the 202 1 Financial Year. FY21 was a strong financial year for Monash IVF and a year we are very proud of , especially considering the challenges the p andemic has presented to our communities. Some of the key factors tha t favoured our business value proposition included a behavioural shift in our patients as COVID - 19 created more focus on families and wellbeing , a strategy that is focused on short and long term tangible growth initiatives, a stable, diverse and specialise d workforce including our clinicians and a n emphasis on patient outcomes. Our Strategy has been clear - with our strategic pillars driving our improved performance , notwithstanding the P andemic. Over the p ast 18 months, the business has benefited from strong and attractive IVF industry fundamentals driving strong growth across our domestic businesses. Monash IVF ’s domestic FY21 Stimulated Cycles increased by 36.6% due to industry growth of 31.1% and we exp erienced market share gains in Monash IVF Group’ s Key M arkets 1 . Market Share in the se Key Markets grew by 0.6% to 21 .0 % and our Vision 2026 strategic plan is anticipated to grow market share in FY22 and beyond. There were various factors which contri but ed to the market share growth experienced in the period, including increased marketing investment, new fertility specialists who join ed Monash IVF Group and the addition of our new Sydney CBD flagship clinic. As a result, o ur Adjusted N et P rofit after tax grew by 61.5% to $23.3m as compared to FY20. We have continued to make investment s in marketing, attraction of new fertility specialists, a dd ed capacity and market presence across Australia and South - East Asia and achieved strong patient, staff and doctor experience and engagement . I look forward to the opening of our new and exciting fertility clinics in Melbourne, Gold Coast, Penrith and Darwin as well as the expansion of our day hospital revenue with new operations in Melbourne and the Gold Coast. We were also pleased to welcome a total of 12 new fertility specialists in FY21 through recruitment, as well as through our internal training program. (1) Key Markets are Victoria, New South Wales, Queensland, South Australia and Northern Territory combined 2 The Board recognises that our dedicated and experienced team is our most important asset, and we continue d to invest in the development of our P eople. The Business has delivered record Doctor and Employee Engagement net promoter score s in FY21 of over 60% and a 6.5% increase in Patient Engagement scores. I would like to thank our dedicated specialists, nurse s, scientists and patient services staff who have worked tirelessly to improve our service and patient outcomes . Trading update I will now provide an update on trading during the first quarter of FY22. Notwithstanding challenging comparative s in the first quarter of FY 21, the IVF b usiness es ha ve continued to grow at strong levels in the period from July to September 2021 , as domestic Stimulated Cycles ha ve grown by 9.0% compared to the prior comparative period. From a market share perspective , during the period from July to September 2021 , Monash IVF Group’s domestic Key Market s 1 Market Share has grown by 1.9% to 22.4% compared to the prior comparative period with market share growth experienced in V ictoria , Q ueensland , S outh Austra lia and N ew South Wales . New Australian IVF patient pipeline through inbound enquiry and patient registration s are continuing at above the historically high prior comparative period levels with new patient registrations increasing by 14.2 % in the period from July to October 2021. New patient registration growth provid es a solid platform for the remainder of FY22. Our Kuala Lumpur clinic is showing positive signs of improvement following a challenging COVID environment during Q1FY22 as Stimulated Cycles declined by 28.1% in the period from July to September 2021. Movement Control Orders in Kuala Lumpur have started to ease during Q2FY22 and performance is anticipated to improve. Our Sydney Ultrasound business is also showing positive signs as it has been impacted by the COV ID - 19 lockdown restrictions in Sydney d uring the period 1 July to 30 September 2021 . Sydney Ultrasound Scans declined by 6.0% during Q1FY22 whilst experiencing a higher cost base to manage safety and health protocols. 1H21 Profit guidance The Company’s NPAT before certain non - regular items for the six - month period ending 31 December 2021 is expected to be approximately $13.0m, as compared to $12.0m in the prior comparative period. Non - regular items for the six - month period ending 31 December 2021 is anticipated to be $0.7 m ( after tax ) relating to costs associated with discontinued acquisition opportunities . T he Group is confident revenue and earnings can grow in 2H22 , subject to any adverse impact from the ongoing Pandemic. T hanks and appreciation We wish to thank our investor shareholders for their continued support during the Pandemic and would like to portray our confidence that the Company is well positioned to grow earnings in FY22 following strong growth in FY21 notwithstanding COVID - 19 challe nges presented in certain markets. I’d like to thank our CEO - Michael Knaap, CFO - Malik Jainudeen, COO – Hamish Hamilton and the rest of the Executive Team for their leadership during the on - going Pandemic and continuing to build a platform for sustai nable growth in the coming years . I am very optimistic for the future of Monash IVF Group as we have laid a strong foundation that is buil t on our clear strategic plan and objectives and a culture that puts the patient at its core which is anticipated to deliver positive outcomes for all stakeholders. I will now invite Mr Knaap to address the meeting to give us an overview of the FY21 operations and a further update on current trading. Approved by the Board of Directors. Michael Knaap Chief Executive Officer and Managing Director Monash IVF Group +61 3 9420 8235 Malik Jainudeen Chief Financial Officer and Company Secretary Monash IVF Group +61 3 9420 8235
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2022 Listcorp. ABN 60 166 140 307

Never miss news from Monash IVF Group Limited (ASX:MVF) when you join Listcorp.